Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

1. tetrabiopharma.com
TSX-V:TBPOTCQB:TBPMF
1 833 977-7575 200-2742, St-Joseph boul. Orleans ON K1C 1G5
Global Leaders in Cannabinoid-Based Drug
Discovery & Development
Cannabinoid: Any of the therapeutic components contained in cannabis,
such as ∆9
Tetrahydrocannabinol (THC), Cannabidiol (CBD), Terpenes...“ ”
TETRA BIO-PHARMA is a Canadian Bio-Pharmaceutical company
that is developing a well-advanced portfolio of five cannabinoid-
based drugs targeting the North American market for terminal
cancer patients, patients suffering from chronic pain as well as
cancer patients suffering from the side effects of chemotherapy.
The company is a global leader in finding and developing cannabinoid-
basedpharmaceuticalproductsandsecuringthemostefficientregulatory
pathway to approval. Aphria Inc. is one of the company's licensed
partners for cannabis production and owns a 8%1
stake in the company.
COMPANY HIGHLIGHTS5
TETRA BIO-PHARMA @ A GLANCE1
1. COMPETITIVE ADVANTAGE – A strong portfolio of cannabinoid-based products offering “first-mover”
advantage over much larger US and Canadian competitors.
2. HIGH GROWTH MARKETS & SIGNIFICANT THERAPEUTIC ADVANTAGES OF CANNABINOIDS –
- More than 100 million North Americans suffer from chronic pain, with one third using opioids with
potentially intolerable side-effects or high risk of addiction
- More than 3 million suffer from Chemotherapy Induced Nausea and Vomiting (CINV)
3.
4.
STRONG INDUSTRY, ACADEMIC AND RESEARCH PARTNERSHIPS – Including Aphria Inc. as Health Canada
licensed producer of medical cannabis, New Brunswick Health Research Fondation, Sante Cannabis, McGill, etc.
5.
SIGNIFICANT CATALYSTS FOR GROWTH – Regulatory milestones in 2018, first USA commercialization
expected in 2019; first Canadian commercialization expected in 2020.
STRONG FINANCING PROFILE – Completed bought deal financing for CAD$11.5 MM and Company stock added
to Leading Cannabis ETF: Horizons Marijuana Life Sciences Index
March
2017
May
2017
July
2017
Sept.
2017
Nov.
2017
Jan.
2018
March
2018
TETRA BIO-PHARMA
Stock price (CAD)
1
Data as of November 30, 2017, non audited 2
Data as of March 20, 2018
3
Data as of September 30, 2017
TETRA FOUNDED 2015
TSX-V (TBP) CAD$0.982
MARKET CAPITALIZATION CAD$124.7MM2
COMMON SHARES 123.8MM1
SHARES FULLY DILUTED 140,4MM1
INSIDER OWNERSHIP 9.4%3
CASH/EQUIVALENT CAD$11.5M2
G&A CASH BURN RATE/MONTH CAD$130K2
FACT SHEET / Q2 2018
0,5
1,0
1,5
2,0

2. tetrabiopharma.com 1 833 977-7575 200-2742, St-Joseph boul. Orleans ON K1C 1G5
TSX-V: TBP OTCQB: TBPMF
Global Leaders in Cannabinoid-Based Drug Discovery & Development
MILESTONES & CATALYSTS LEADERSHIP TEAM PROFILES
TETRA BIO-PHARMA PHARMACEUTICAL PRODUCT PIPELINE
Q4 2017 › Launch of Rx Princeps™ through Aphria
Q1 2018 › Start of PPP001 Phase III Clinical Trial
› Start of PPP005 (cannabis oils) Phase 1 & 2 clinical trials
› Obtention of FDA’s Orphan Drug Designation for PPP001
in Treatment of Complex Regional Pain Syndrome in the US
› Comparative pharmacokinetic study of Dronabinol
XL AdVersa® (PPP002) versus the listed drug in the US
Q2 2018 › CTA filing Phase 1 trial for PPP003 (Ophthalmic)
and PPP004 (Topical)
› Launch of Rx Oil capsules under ACMPR through Aphria
Q4 2018 › Results of PPP001 Phase III Clinical Trial
› Launch of retail line of cannabinoid-based natural health
products in Pharmacy (if legalization occurs in Fall 2018)
2019 › Submission of PPP001 (Smokable) to Health Canada
in order to obtain the first DIN for a smokable drug
› Filing of NDA for PPP002 (Mucoadhesive) in the US
› Expansion of retail line of cannabinoid-based
natural health products
Dr. Chamberland has over 22 years’ experience in the
development of complex drugs in the pharmaceutical
industry (Canada and USA) with an expertise in regula-
tory affairs and in the development of clinical research
protocols for botanical medicines and the manage-
ment of these clinical studies. Dr Chamberland is also a
Master Herbalist.
Guy Chamberland, M.Sc., Ph.D. /
Chief Executive Officer &Chief Scientific Officer
Mr. Lessard has considerable experience as an
executive in the life sciences sector serving as a
member of the c-suite and as a trusted advisor to the
board of directors in managing business strategy and
research teams.
Bernard Lessard,MBA, CPA, CMA /
Chief Financial Officer
INVESTOR RELATION CONTACT
investors@tetrabiopharma.com
438 504-5784
Legal disclaimer. This document contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the
expectations and projections of Tetra Bio-Pharma Inc. The information contained in this document has not been approved or disapproved by any Securities Commission in Canada, The Securities
and Exchange Commission in the US or other regulatory body. Except for statements of historical fact relating to the Company, certain information contained herein constitutes "forward-looking
statements". Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate" and other similar words, or statements that certain
events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks
and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These factors include the inherent risks involved
in the development of botanical based pharmaceuticals or medical devices regulated by Health Canada, the FDA or other international regulatory agencies, product obsolescence, the uncertainties
involved in patent defense and complexities and timelines associated with product approvals in multiple jurisdictions, the possibility of project cost overruns or unanticipated costs and expenses,
uncertainties relating to the availability and costs of financing needed in the future and other factors. Circumstances or management's estimates or opinions could change. The reader is cautioned not
to place undue reliance on forward-looking statements. Except as required by law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result
of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any
representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation.
Q3 2018
DISCOVERY
Advanced cancer pain
PRE-CLINICAL CTA/IND PHASE 1 PHASE 2 PHASE 3
MARKETING APPL
DEVELOPMENT PARTNERPHASE 4
PPP005 PPP005
Chemotherapy induced
nausea & vomiting
Chronic pain
Treatment for ocular
pain & inflammation
Topical cream for treatment
of neuropathic pain
Oral capsules of cannabis oil
for treatment of chronic pain
PPP001
PPP003
PPP004
PPP002 - DRONABINOL XL
PPP002 - DRONABINOL XL